AIMS/HYPOTHESIS: Type 2 diabetes mellitus is characterised by increased plasma NEFA and IL-6 concentrations, and IL-6 increases lipolysis in healthy men. We assessed the adipose tissue hormone-sensitive lipase (HSL) mRNA expression, protein expression and HSL activity in patients with type 2 diabetes mellitus, and determined the effect of IL-6 administration on these measures. METHODS: Seven patients with type 2 diabetes mellitus (age 67+/-4 years, weight 87+/-7 kg) and six age- and weight-matched individuals visited the laboratory on two occasions. Subcutaneous adipose tissue biopsies and blood samples were obtained prior to and during 3 h of either saline or recombinant human IL-6 infusion. RESULTS: HSL mRNA was reduced (p<0.05) by approximately 40% in type 2 diabetes mellitus relative to control subjects, while HSL protein expression showed a tendency to be decreased (35%, p=0.09). HSL activity averaged 8.87+/-1.25 and 6.91+/-1.20 nmol min(-1) mg(-1) protein for control and type 2 diabetic subjects respectively (p<0.05). IL-6 administration increased (p<0.05) HSL mRNA 2-fold at 60 min in both groups, whereas HSL protein and activity were unaffected by IL-6. Plasma insulin was elevated (p<0.05) in patients with type 2 diabetes mellitus at rest and was blunted (p<0.05) during IL-6 infusion in both groups. Plasma glucagon and cortisol were elevated (p<0.05) by IL-6 in both groups. CONCLUSIONS/ INTERPRETATION: Our data demonstrate that basal HSL is decreased in patients with type 2 diabetes mellitus, and this may be a consequence of elevated plasma insulin levels. We have also shown that IL-6 administration increases HSL gene expression, although it exerted no effect on HSL protein and activity. This disparity between mRNA, protein and enzyme activity may be a function either of the marked alterations in the hormonal milieu induced by IL-6 administration and/or of post-transcriptional events.
AIMS/HYPOTHESIS: Type 2 diabetes mellitus is characterised by increased plasma NEFA and IL-6 concentrations, and IL-6 increases lipolysis in healthy men. We assessed the adipose tissue hormone-sensitive lipase (HSL) mRNA expression, protein expression and HSL activity in patients with type 2 diabetes mellitus, and determined the effect of IL-6 administration on these measures. METHODS: Seven patients with type 2 diabetes mellitus (age 67+/-4 years, weight 87+/-7 kg) and six age- and weight-matched individuals visited the laboratory on two occasions. Subcutaneous adipose tissue biopsies and blood samples were obtained prior to and during 3 h of either saline or recombinant humanIL-6 infusion. RESULTS:HSL mRNA was reduced (p<0.05) by approximately 40% in type 2 diabetes mellitus relative to control subjects, while HSL protein expression showed a tendency to be decreased (35%, p=0.09). HSL activity averaged 8.87+/-1.25 and 6.91+/-1.20 nmol min(-1) mg(-1) protein for control and type 2 diabetic subjects respectively (p<0.05). IL-6 administration increased (p<0.05) HSL mRNA 2-fold at 60 min in both groups, whereas HSL protein and activity were unaffected by IL-6. Plasma insulin was elevated (p<0.05) in patients with type 2 diabetes mellitus at rest and was blunted (p<0.05) during IL-6 infusion in both groups. Plasma glucagon and cortisol were elevated (p<0.05) by IL-6 in both groups. CONCLUSIONS/ INTERPRETATION: Our data demonstrate that basal HSL is decreased in patients with type 2 diabetes mellitus, and this may be a consequence of elevated plasma insulin levels. We have also shown that IL-6 administration increases HSL gene expression, although it exerted no effect on HSL protein and activity. This disparity between mRNA, protein and enzyme activity may be a function either of the marked alterations in the hormonal milieu induced by IL-6 administration and/or of post-transcriptional events.
Authors: Sandra C Souza; Kizito V Muliro; Laura Liscum; Ping Lien; Mia T Yamamoto; Jean E Schaffer; Gerard E Dallal; Xinzhong Wang; Fredric B Kraemer; Martin Obin; Andrew S Greenberg Journal: J Biol Chem Date: 2001-12-20 Impact factor: 5.157
Authors: Guenter Haemmerle; Robert Zimmermann; Marianne Hayn; Christian Theussl; Georg Waeg; Elke Wagner; Wolfgang Sattler; Thomas M Magin; Erwin F Wagner; Rudolf Zechner Journal: J Biol Chem Date: 2001-11-20 Impact factor: 5.157
Authors: G Costabile; G Annuzzi; L Di Marino; C De Natale; R Giacco; L Bozzetto; P Cipriano; C Santangelo; R Masella; A A Rivellese Journal: J Endocrinol Invest Date: 2010-10-04 Impact factor: 4.256
Authors: João Paulo Camporez; Kun Lyu; Emily L Goldberg; Dongyan Zhang; Gary W Cline; Michael J Jurczak; Vishwa Deep Dixit; Kitt Falk Petersen; Gerald I Shulman Journal: J Physiol Date: 2019-07-04 Impact factor: 5.182
Authors: Jian Shen; Donna K Arnett; Pablo Pérez-Martínez; Laurence D Parnell; Chao-Qiang Lai; James M Peacock; James E Hixson; Michael Y Tsai; Robert J Straka; Paul N Hopkins; José M Ordovás Journal: J Lipid Res Date: 2008-04-16 Impact factor: 5.922
Authors: Stefan Z Lutz; Anita M Hennige; Susanne Feil; Andreas Peter; Andrea Gerling; Jürgen Machann; Stefan M Kröber; Michaela Rath; Annette Schürmann; Cora Weigert; Hans-Ulrich Häring; Robert Feil Journal: Diabetes Date: 2011-04-04 Impact factor: 9.461
Authors: Jakob G Knudsen; Anders Gudiksen; Lærke Bertholdt; Peter Overby; Ida Villesen; Camilla L Schwartz; Henriette Pilegaard Journal: PLoS One Date: 2017-12-18 Impact factor: 3.240
Authors: Margareta Jernås; Bob Olsson; Peter Arner; Peter Jacobson; Lars Sjöström; Andrew Walley; Philippe Froguel; Philip G McTernan; Johan Hoffstedt; Lena M S Carlsson Journal: Biochem Biophys Res Commun Date: 2009-03-28 Impact factor: 3.575